Pureanto stg n

Blood samples were collected early in the morning after at least 12-h fasting, through a venous line placed in the median vein using an indwelling catheter. PG level was measured with the glucose oxidase method. HbA1c was measured via high-performance liquid chromatography (HPLC) using a Tosoh HLC-723G8 (Tosoh, Kyoto, Japan). HbA1c (%) was estimated as the National Glycohemoglobin Standardization Program (NGSP) equivalent value, which was calculated as HbA1c (NGSP) (%) = HbA1c (JDS) (%) + 0.4%, considering the relationship of HbA1c (NGSP) values to HbA1c (JDS) (%) values determined by the Japanese standard and measurement method. HOMA-IR, which represents insulin resistance, was calculated using the following formula: HOMA-IR = Fasting glucose level × Fasting insulin level ÷ 405. Measurement of lipid profiles and other markers was outsourced to SRL Co. (Tokyo, Japan). Plasma lipid was measured with a Hitachi 7,350 autoanalyzer (Hitachi, Tokyo, Japan). LDL-C was measured using the colestest LDL (Sekisui Medical, Tokyo, Japan) by the direct method. HDL-C was measured using the colestest NHDL (Sekisui Medical) by the direct method. TG was measured using the pureanto STG-N (Sekisui Medical) by the enzymatic method. HMW-AN was measured via a chemiluminescent enzyme immunoassay. u-C-peptide reactivity (CPR) level was measured in 24-h urine samples.

Measurements of serum lipid profile and other parameters were outsourced to SRL Co. (Tokyo, Japan). Plasma lipid was measured with a Hitachi 7350 autoanalyzer (Hitachi Co., Tokyo, Japan). LDL‐C was measured using the colestest LDL (Sekisui Medical, Tokyo, Japan) by the direct method. HDL‐C was measured using the Cholestest NHDL (Sekisui Medical) by the direct method. TG was measured using the pureanto STG‐N (Sekisui Medical) by the enzymatic method. FFA was measured using the NEFA‐SS”EIKEN” (Eiken Kagaku, Tokyo, Japan) by the enzymatic method. Furthermore, sdLDL‐C was measured using the sdLDL‐EX reagent “SEIKEN” (Denka Seiken Inc., Tokyo, Japan) by the enzymatic method. MDA LDL‐C was measured using the oxidative ELISA “Daiichi” (Sekisui Medical) by the sandwich enzyme‐linked immunosorbent assay method. ApoB‐48 was measured using a chemiluminescence enzyme immunoassay (CLEIA; Fuji Rebio Inc, Tokyo, Japan)7. ApoB‐100 was measured using a turbidimetric immunoassay (TIA; Daiichi Kagaku, Tokyo, Japan). All samples were stored at −80°C until measurement.